ArticleThe Biochemical journal2025
A minimum catalytic unit for synthesis of InsP6 and 5-PP-InsP5 in Arabidopsis.
Article in The Biochemical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Inositol pyrophosphates (diphosphoinositol phosphates) are reported agents of phosphate homeostasis, disease resistance, and hormone action in plants. Of the enzymes that have been shown to synthesize inositol pyrophosphates, inositol tris/tetrakisphosphate (ITPK)1 and Arabidopsis thaliana diphosphoinositol pentakisphosphate kinase (VIH)1/VIH2 share the ATP-grasp fold-the latter also possesses a phosphatase domain. Among ATP-grasp inositol phosphate kinases, ITPK1 is particularly flexible-phosphorylating equatorial hydroxyls and equatorial phosphates on inositol phosphates. Herein, we show that the combination of ITPK1 and inositol pentakisphosphate 2-kinase (IPK1) is sufficient to synthesize 5-PP-InsP5 from 1D-myo-inositol 3-monophosphate (Ins3P) and that ITPK1 is capable of converting 1D-myo-inositol 1-monophosphate to myo-inositol 1,3,4,5,6-pentakisphosphate [Ins(1,3,4,5,6)P5]. In defining a minimal catalytic unit for synthesis of both myo-inositol 1,2,3,4,5,6-hexakisphosphate (InsP6/Ins(1,2,3,4,5,6)P6) and 5-PP-InsP5, we define the minimum enzymology of the 'lipid-independent' pathway of InsP6 synthesis from Ins3P and its intermediates. The pathway proceeds: Ins3P, 1D-myo-inositol 3,4-bisphosphate, 1D-myo-inositol 3,4,5-trisphosphate, 1D-myo-inositol 3,4,5,6-tetrakisphosphate, Ins(1,3,4,5,6)P5, Ins(1,2,3,4,5,6)P6, and therefrom to 5-diphosphoinositol-1,2,3,4,6-pentakisphosphate [5-PP-Ins(1,2,3,4,6)P5].
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.